Dr Dean Corbett is proud to be participating in the "CLEAR" (CLinical Evaluation of the FluidVision® MX AIOL for Accommodating Restoration) study which will evaluate the safety and effectiveness of an investigational device for cataract patients called the FluidVision MX Accommodating Intraocular Lens (AIOL). The FluidVIsion AIOL has been approved for research but not for sale yet.
The enrolment of patients for this study has commenced and this study will compare the safety and effectiveness of the FluidVision AIOL to the AcrySof® IQ PanOptix® trifocal IOL in patients who need cataract surgery in both eyes.
In the CLEAR study, eligible patients have a 50/50 chance to be randomly chosen to receive either the FluidVision AIOL or the PanOptix trifocal in both eyes.
Patients that meet the following criteria may be eligible:
- Patient is 50 years of age or older and has not had previous refractive, intraocular or corneal surgery in either eye
- Patient has cataracts in both eyes (best corrected distance visual acuity worse than 20/40 (or 6/12) in each eye or visually significant symptoms such as poor night vision)
- Patient has pre-operative or predicted post-operative keratometric astigmatism of ≤ 1.00 Diopter
- Patient has no other ocular conditions, degenerative visual disorders or systemic diseases
- Patient does not use medications that may affect accommodation
- Patient is willing and physically able to wear contact lenses, if required
For more information, please refer to the CLEAR Study website: http://www.myclearstudy.com/
Alternatively, if you have patients to refer, please contact May Mendoza by phone 09 529 2480 or email at: firstname.lastname@example.org
To learn more about this study, visit: https://www.aucklandeye.co.nz/about/news/new-iol-trialled-at-auckland-eye/